Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

539109 PAR-2 Agonist I - Calbiochem

539109
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

Empirical Formula
C₃₁H₅₃N₉O₇

Products

RéférenceConditionnement Qté
539109-1MG Ampoule plast. 1 mg
539109-5MG Ampoule plast. 5 mg
Description
OverviewThe native PAR-2-specific agonist, SLIGRL-NH2, is modified with an N-terminal furoyl group to increase its potency and resistance to metabolic degradation. Shown to activate [Ca2+]i mobilization in PAR-2-expressing cells (EC50 = 253 nM using HCT-15 cells) in vitro and induce PAR-2 mediated salivation (ED50 = 30 nmol/kg, i.v.) in vivo, while exhibiting no effect on PAR-2-/- mice. Reactive towards human, rat, and murine PAR-2.
Catalogue Number539109
Brand Family Calbiochem®
SynonymsProteinase Activated Receptor-2 Agonist I, 2f-LIGRL-amide
References
ReferencesKawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 108.
Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 1098.
Ferrell, W.R., et al. 2003. J. Clin. Invest. 111, 35.
Product Information
ATP CompetitiveN
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Hill FormulaC₃₁H₅₃N₉O₇
Chemical formulaC₃₁H₅₃N₉O₇
Hygroscopic Hygroscopic
ReversibleN
Quality LevelMQ100
Applications
Biological Information
Primary TargetPAR-2
Primary Target IC<sub>50</sub>EC50 = 253 nM as PAR-2-specific agonist using HCT-15 cells
Purity≥95% by HPLC
Physicochemical Information
Cell permeableN
Peptide Sequence2-Furoyl-Leu-Ile-Gly-Arg-Leu-NH₂
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
539109-1MG 04055977195309
539109-5MG 04055977195316

Documentation

PAR-2 Agonist I - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

PAR-2 Agonist I - Calbiochem Certificats d'analyse

TitreNuméro de lot
539109

Références bibliographiques

Aperçu de la référence bibliographique
Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 108.
Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 1098.
Ferrell, W.R., et al. 2003. J. Clin. Invest. 111, 35.
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision02-September-2008 RFH
SynonymsProteinase Activated Receptor-2 Agonist I, 2f-LIGRL-amide
DescriptionNative proteinase activated receptor-2- (PAR-2) specific agonist, SLIGRL-NH2, modified with an N-terminal furoyl group to increase its potency and resistance to metabolic degradation. Shown to activate [Ca2+]i mobilization in PAR-2-expressing cells (EC50 = 253 nM in HCT-15 cells) in vitro. Also induces PAR-2-mediated salivation (ED50 = 30 nmol/kg, i.v.) in vivo. Exhibits no effects on PAR-2-/- mice. Reactive towards human, rat, and mouse PAR-2.
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₃₁H₅₃N₉O₇
Peptide Sequence2-Furoyl-Leu-Ile-Gly-Arg-Leu-NH₂
Purity≥95% by HPLC
SolubilityDMSO (5 mg/ml)
Storage +2°C to +8°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesKawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 108.
Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 1098.
Ferrell, W.R., et al. 2003. J. Clin. Invest. 111, 35.